International Journal of Hematology最新文献

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in Japan: changes in practice patterns and outcomes during the past 20 years. 日本急性髓性白血病的异基因造血细胞移植：过去20年的实践模式和结果的变化。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-05-04 DOI: 10.1007/s12185-026-04223-0

Masamitsu Yanada, Yoshimitsu Shimomura, Satoshi Yamasaki, Shohei Mizuno, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Masatsugu Tanaka, Tetsuya Nishida, Tetsuya Eto, Yuta Katayama, Satoshi Yoshihara, Shuichi Ota, Yuta Hasegawa, Makoto Onizuka, Toshiro Kawakita, Masashi Sawa, Koji Kawamura, Junya Kanda, Yoshiko Atsuta, Takaaki Konuma

{"title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in Japan: changes in practice patterns and outcomes during the past 20 years.","authors":"Masamitsu Yanada, Yoshimitsu Shimomura, Satoshi Yamasaki, Shohei Mizuno, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Masatsugu Tanaka, Tetsuya Nishida, Tetsuya Eto, Yuta Katayama, Satoshi Yoshihara, Shuichi Ota, Yuta Hasegawa, Makoto Onizuka, Toshiro Kawakita, Masashi Sawa, Koji Kawamura, Junya Kanda, Yoshiko Atsuta, Takaaki Konuma","doi":"10.1007/s12185-026-04223-0","DOIUrl":"https://doi.org/10.1007/s12185-026-04223-0","url":null,"abstract":"This study examined changes in practice patterns and outcomes of allogeneic hematopoietic cell transplantation (HCT) over the past 20 years. Data were analyzed from a Japanese nationwide registry of consecutive adult patients with acute myeloid leukemia who underwent allogeneic HCT between 2001 and 2020. The study population included 17,553 patients, of whom 6653 underwent allogeneic HCT in 2001-2010 and 10,900 in 2011-2020. Patients in the later period were older, were more likely to be in first complete remission, and more frequently received umbilical cord blood transplantation. After adjusting for major covariates, the 2011-2020 cohort had lower risks of overall mortality (hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.80-0.89; P < 0.001), relapse (HR, 0.88; 95% CI, 0.83-0.95; P < 0.001), and non-relapse mortality (NRM; HR, 0.88; 95% CI, 0.81-0.95; P < 0.001). Subgroup analyses revealed improvements in overall survival (OS) regardless of age and disease status. The study found significant changes in allogeneic HCT practice in Japan and showed that the dual decrease in the risks of relapse and NRM contributed to the OS improvement, highlighting the substantial progress in this field over the past two decades.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rapid regression of a bulky cranial lesion in high-risk multiple myeloma with isatuximab-based quadruplet induction. 以依沙妥昔单抗为基础的四联体诱导在高风险多发性骨髓瘤中大面积颅脑病变的快速消退。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-04-26 DOI: 10.1007/s12185-026-04216-z

Shun Ito, Takahiro Namiki, Hironao Nukariya, Toshihide Endo, Yoshihisa Sugawasa, Takashi Ichinohe, Kazuya Kurihara, Takashi Hamada, Shimon Otake, Hiromichi Takahashi, Hideki Nakamura, Shihoko Komine-Aizawa, Katsuhiro Miura

{"title":"Rapid regression of a bulky cranial lesion in high-risk multiple myeloma with isatuximab-based quadruplet induction.","authors":"Shun Ito, Takahiro Namiki, Hironao Nukariya, Toshihide Endo, Yoshihisa Sugawasa, Takashi Ichinohe, Kazuya Kurihara, Takashi Hamada, Shimon Otake, Hiromichi Takahashi, Hideki Nakamura, Shihoko Komine-Aizawa, Katsuhiro Miura","doi":"10.1007/s12185-026-04216-z","DOIUrl":"https://doi.org/10.1007/s12185-026-04216-z","url":null,"abstract":"A 77-year-old woman with newly diagnosed immunoglobulin (Ig)G-κ multiple myeloma presented with a massive cranial paraskeletal (PS) lesion (84 × 59 × 62 mm) compressing the occipital lobe. Fluorescence in situ hybridization of bone marrow aspirate revealed 1q21 gain and 17p deletion. Induction therapy with isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) was initiated to avoid emergent local intervention. The response was rapid; head computed tomography on day 28 showed an approximately 80% reduction in bidimensional measurements, with near-complete radiologic resolution by the end of the second cycle. After the third cycle, elective reconstructive cranioplasty was performed. Although a pretreatment biopsy was not feasible, the resected tissue showed no detectable plasma cells. Measurable residual disease in the bone marrow was negative (< 10-5) after the fourth cycle. Exploratory longitudinal flow cytometry of the peripheral blood revealed baseline expansion of CD8-positive terminally differentiated effector memory re-expressing CD45RA (TEMRA) cells and persistent TEMRA subset dominance after the fourth cycle. This case suggests that upfront anti-CD38 antibody-containing quadruplet therapy can enable deferral of urgent local intervention through rapid cytoreduction in select patients with bulky cranial PS involvement, even in older adults with high-risk cytogenetic features and compromised immune profiles.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147771037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in the pathophysiology and treatment of GVHD. GVHD的病理生理及治疗进展。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-04-26 DOI: 10.1007/s12185-026-04218-x

Junichi Sugita

引用次数: 0

Splenic rupture secondary to pegfilgrastim in a healthy allogeneic peripheral blood hematopoietic stem cell donor. 聚非格昔汀致健康异体外周血造血干细胞供者脾破裂。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-04-24 DOI: 10.1007/s12185-026-04214-1

Ryo Takahashi, Koichi Oya, Yuki Ishizawa, Yusuke Nagano, Ryo Sato, Masashi Hosokawa, Akane Yamada, Takuma Suzuki, Keiko Aizawa, Satoshi Ito, Daniel Peltier, Hisayuki Yokoyama, Tomomi Toubai

{"title":"Splenic rupture secondary to pegfilgrastim in a healthy allogeneic peripheral blood hematopoietic stem cell donor.","authors":"Ryo Takahashi, Koichi Oya, Yuki Ishizawa, Yusuke Nagano, Ryo Sato, Masashi Hosokawa, Akane Yamada, Takuma Suzuki, Keiko Aizawa, Satoshi Ito, Daniel Peltier, Hisayuki Yokoyama, Tomomi Toubai","doi":"10.1007/s12185-026-04214-1","DOIUrl":"https://doi.org/10.1007/s12185-026-04214-1","url":null,"abstract":"Granulocyte-colony stimulating factor (G-CSF) is widely used to mobilize peripheral blood stem cells (PBSCs) for hematopoietic cell transplantation (HCT). G-CSF is generally well-tolerated but can cause life-threatening complications such as splenic rupture in rare cases. Long-acting pegfilgrastim (Peg-G) is increasingly used for PBSC mobilization, but its risk for splenic rupture is less well characterized. Here, we report a case of splenic rupture secondary to Peg-G administered for PBSC mobilization in a healthy 25-year-old male haploidentical donor. He presented with left upper quadrant abdominal pain shortly after PBSC harvest 5 days following administration of Peg-G. Computed tomography (CT) revealed splenomegaly with rupture, and small bloody peri-splenic and pelvic ascites. He was managed conservatively, but the next evening his symptoms temporarily worsened, prompting a repeat CT scan, which showed no change. Thereafter, the pain did not recur, and the patient was discharged on day 8. One month later, a follow-up CT demonstrated complete resolution. To our knowledge, this is the first case of splenic rupture secondary to Peg-G for PBSC mobilization in a healthy allogeneic donor and highlights the importance of vigilance for this rare complication when G-CSF or Peg-G is used for mobilization.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147771043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Philadelphia chromosome-negative but BCR::ABL1-positive acute lymphoblastic leukemia: a real-world multicenter cohort study. 费城染色体阴性但BCR:: abl1阳性的急性淋巴细胞白血病：一项真实世界的多中心队列研究

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-04-22 DOI: 10.1007/s12185-026-04212-3

Shota Yokoyama, Masahiro Onozawa, Hiroyuki Kimura, Takahide Ara, Jun Nagai, Shota Yoshida, Naoki Miyashita, Toshihiro Matsukawa, Hideki Goto, Shinsuke Hirabayashi, Minoru Kanaya, Akio Mori, Daisuke Hidaka, Junichi Hashiguchi, Kentaro Wakasa, Makoto Ibata, Yukari Takeda, Takuto Miyagishima, Satoshi Yamamoto, Katsuya Fujimoto, Toma Suzuki, Tomoyuki Saga, Hajime Sakai, Yasutaka Kakinoki, Tatsuo Oyake, Takeshi Kondo, Takanori Teshima

{"title":"Philadelphia chromosome-negative but BCR::ABL1-positive acute lymphoblastic leukemia: a real-world multicenter cohort study.","authors":"Shota Yokoyama, Masahiro Onozawa, Hiroyuki Kimura, Takahide Ara, Jun Nagai, Shota Yoshida, Naoki Miyashita, Toshihiro Matsukawa, Hideki Goto, Shinsuke Hirabayashi, Minoru Kanaya, Akio Mori, Daisuke Hidaka, Junichi Hashiguchi, Kentaro Wakasa, Makoto Ibata, Yukari Takeda, Takuto Miyagishima, Satoshi Yamamoto, Katsuya Fujimoto, Toma Suzuki, Tomoyuki Saga, Hajime Sakai, Yasutaka Kakinoki, Tatsuo Oyake, Takeshi Kondo, Takanori Teshima","doi":"10.1007/s12185-026-04212-3","DOIUrl":"https://doi.org/10.1007/s12185-026-04212-3","url":null,"abstract":"Chronic myelogenous leukemia that carries the BCR::ABL1 fusion gene without cytogenetically detectable Philadelphia (Ph) chromosomes is termed masked Ph. However, the prevalence and clinical relevance of masked Ph in acute lymphoblastic leukemia (ALL) remain unclear. Using the Hokkaido Leukemia Net real-world multicenter cohort, we analyzed 160 B-cell ALL patients diagnosed between 2017 and 2024 with available cytogenetic and molecular data. Among 92 BCR::ABL1-positive cases, 19 (20.7%) lacked a cytogenetically visible Ph chromosome and were classified as masked-Ph ALL. Compared with Ph + ALL, masked-Ph patients were older and had lower white blood cell counts and bone marrow blast percentages at diagnosis. Most BCR::ABL1-positive patients received tyrosine kinase inhibitors (TKIs) during induction, resulting in comparable complete remission rates and similar overall survival between masked-Ph and Ph + ALL; both groups showed superior outcomes compared with BCR::ABL1-negative ALL. The number of metaphases analyzed by G-banding was significantly lower in masked-Ph ALL, suggesting underdetection by conventional cytogenetics. One case exhibited an atypical FISH pattern consistent with a cryptic microinsertion. These findings indicate that masked-Ph ALL is relatively common and may be overlooked without molecular testing, underscoring the importance of incorporating RT-PCR and FISH at diagnosis.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Zanubrutinib for MYD88-negative Waldenström's macroglobulinemia with massive splenomegaly. 扎鲁替尼治疗myd88阴性Waldenström巨球蛋白血症伴脾肿大。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-04-19 DOI: 10.1007/s12185-026-04215-0

Takashi Onaka, Kazunori Imada

引用次数: 0

Impact of lymphocyte p-glycoprotein activity on development of graft-versus-host disease after stem cell transplantation. 淋巴细胞p-糖蛋白活性对干细胞移植后移植物抗宿主病发生的影响。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-04-15 DOI: 10.1007/s12185-026-04196-0

Shoji Nakamura, Soichiro Tajima, Takeshi Hirota, Koji Kato, Koichi Akashi, Mayako Uchida

{"title":"Impact of lymphocyte p-glycoprotein activity on development of graft-versus-host disease after stem cell transplantation.","authors":"Shoji Nakamura, Soichiro Tajima, Takeshi Hirota, Koji Kato, Koichi Akashi, Mayako Uchida","doi":"10.1007/s12185-026-04196-0","DOIUrl":"10.1007/s12185-026-04196-0","url":null,"abstract":"Tacrolimus (TAC) is a pivotal immunosuppressant used to prevent graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation (HSCT). However, because lymphocytes express P-glycoprotein (P-gp), which actively effluxes TAC, blood TAC concentrations do not necessarily reflect intracellular drug levels. Rather, the expression and activity of P-gp are influenced by multiple factors that change dynamically after transplantation, including inflammatory cytokines and gut microbiota. This study longitudinally assessed P-gp activity in peripheral blood mononuclear cells from HSCT recipients. Serial measurements were taken between days 14 and 41 following transplantation. Although blood TAC trough concentrations remained within the therapeutic range (10-15 ng/mL) throughout this period, P-gp activity increased progressively from the early (days 14-17) to the intermediate (days 38-41) post-transplantation phases. Notably, although the TAC blood concentration did not change significantly between days 14 and 17 and GVHD onset, P-gp activity was significantly elevated at GVHD onset (p < 0.05). These findings suggest fluctuations in P-gp activity may play a role in the onset of GVHD. Early assessment of P-gp activity after HSCT may serve as a biomarker for predicting GVHD development; however, further studies are required to validate its clinical utility.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147690065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Belantamab mafodotin, bortezomib, and dexamethasone for RRMM in the Japan expansion cohort of the phase 3 DREAMM-7 trial. 贝兰他单-马弗多汀、硼替佐米和地塞米松治疗RRMM在日本扩展队列的3期dream -7试验。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-04-15 DOI: 10.1007/s12185-026-04211-4

Tomoaki Fujisaki, Kohmei Kubo, Yasushi Hiramatsu, Ryosuke Ogawa, Taeko Yonekawa, Akira Endo, Hirofumi Nakano, Joe Lee, Lydia Eccersley, Hena Baig, Eric Lewis, Taku Fujii

{"title":"Belantamab mafodotin, bortezomib, and dexamethasone for RRMM in the Japan expansion cohort of the phase 3 DREAMM-7 trial.","authors":"Tomoaki Fujisaki, Kohmei Kubo, Yasushi Hiramatsu, Ryosuke Ogawa, Taeko Yonekawa, Akira Endo, Hirofumi Nakano, Joe Lee, Lydia Eccersley, Hena Baig, Eric Lewis, Taku Fujii","doi":"10.1007/s12185-026-04211-4","DOIUrl":"https://doi.org/10.1007/s12185-026-04211-4","url":null,"abstract":"The randomized, phase 3 DREAMM-7 trial (NCT04246047) previously demonstrated the efficacy and safety of belantamab mafodotin, bortezomib, and dexamethasone (BVd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM) and ≥ 1 prior therapy. The results in the Japan expansion cohort of DREAMM-7, consisting of 24 patients randomized to receive BVd (N = 10) or DVd (N = 14), are presented here. The median follow-up was 19.4 months (range, 1.3-30.3). Median progression-free survival (PFS) was not reached (NR; 95% CI, 7.0-NR) with BVd versus 11.1 months (95% CI, 4.9-NR) with DVd (PFS hazard ratio, 0.40; 95% CI, 0.11-1.52). The overall response rate was 90.0% (95% CI, 55.5-99.7) versus 71.4% (95% CI, 41.9-91.6); median duration of response was NR (95% CI, 9.7-NR) versus 14.5 months (95% CI, 3.5-NR). Safety trends in the Japan expansion cohort were similar to those in the global cohort. Ocular adverse reactions were more common with BVd and were manageable with dose modification. No new safety signals were reported. As in the global cohort, results in the Japan expansion cohort demonstrated the safety and efficacy of BVd in patients with RRMM and ≥ 1 prior therapy.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147690068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selection of anti-CD38 antibodies for flow cytometric detection of myeloma cells treated with daratumumab or isatuximab. 选择抗cd38抗体用于达拉单抗或依沙妥昔单抗治疗的骨髓瘤细胞的流式细胞术检测。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-04-13 DOI: 10.1007/s12185-026-04210-5

Yusuke Inoue, Takeshi Harada, Asuka Oda, Natsumi Ohara, Hiromi Nakagawa, Minami Urushihara, Takayuki Nakao, Ken-Ichi Matsuoka

{"title":"Selection of anti-CD38 antibodies for flow cytometric detection of myeloma cells treated with daratumumab or isatuximab.","authors":"Yusuke Inoue, Takeshi Harada, Asuka Oda, Natsumi Ohara, Hiromi Nakagawa, Minami Urushihara, Takayuki Nakao, Ken-Ichi Matsuoka","doi":"10.1007/s12185-026-04210-5","DOIUrl":"https://doi.org/10.1007/s12185-026-04210-5","url":null,"abstract":"Treatment with the anti-CD38 therapeutic monoclonal antibodies (mAbs) daratumumab (DARA) and isatuximab (ISA) achieves deep responses in patients with multiple myeloma (MM), often resulting in measurable residual disease (MRD) negativity. CD38 is one of the key surface markers used for flow cytometric MRD assessment in MM; however, DARA is known to interfere with CD38 detection by conventional anti-CD38 mAbs. The impact of ISA on CD38 detection remains unclear. This study aimed to develop optimized methods for accurate detection of CD38 on MM cells by flow cytometry. The anti-CD38-variable heavy chain of heavy chain (VHH) Ab from the JK36 clone enabled clearer detection of surface CD38 on DARA-treated MM cells compared with the anti-CD38 multi-epitope (ME) Abs and anti-CD38 mAbs (T16 and HB7 clones). In contrast, in ISA-treated MM cells, the anti-CD38 mAbs demonstrated superior CD38 detection compared with the anti-CD38 ME Ab and anti-CD38 VHH Ab. These trends were confirmed in primary bone marrow samples from MM patients treated with anti-CD38 therapeutic mAbs. These findings underscore the importance of selecting appropriate anti-CD38 Abs based on treatment history to ensure accurate flow cytometric evaluation of MM cells in patients treated with DARA or ISA.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147673012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Defibrotide for late-onset sinusoidal obstruction syndrome following umbilical cord blood transplantation: a single-center retrospective study. 去纤维肽治疗脐带血移植后迟发性窦阻塞综合征：一项单中心回顾性研究。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-04-13 DOI: 10.1007/s12185-026-04209-y

Yuki Shimizu, Shinsuke Takagi, Maki Higuchi, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Daisuke Kaji, Aya Nishida, Hisashi Yamamoto, Hideki Araoka, Yuki Asano-Mori, Go Yamamoto, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida

{"title":"Defibrotide for late-onset sinusoidal obstruction syndrome following umbilical cord blood transplantation: a single-center retrospective study.","authors":"Yuki Shimizu, Shinsuke Takagi, Maki Higuchi, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Daisuke Kaji, Aya Nishida, Hisashi Yamamoto, Hideki Araoka, Yuki Asano-Mori, Go Yamamoto, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida","doi":"10.1007/s12185-026-04209-y","DOIUrl":"https://doi.org/10.1007/s12185-026-04209-y","url":null,"abstract":"Late-onset sinusoidal obstruction syndrome (SOS) after allogeneic hematopoietic cell transplantation remains difficult to diagnose and treat. We retrospectively analyzed 14 umbilical cord blood transplant recipients who developed late-onset SOS and received defibrotide at Toranomon Hospital between 2019 and 2021. All patients presented with very severe SOS accompanied by multiorgan failure. The cumulative incidence of complete remission was 35.7% at one year after initiation of defibrotide therapy. Overall survival was 57.1% at day 100 and 35.7% at two years after SOS diagnosis. Patients with anicteric SOS tended to have better survival than those with icteric disease. Defibrotide was generally well tolerated, with only two grade ≥ 3 bleeding events. Despite the small sample size and retrospective design, these findings suggest that Defibrotide may provide clinical benefit in patients with late-onset SOS following umbilical cord blood transplantation.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147673008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0